Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Final CTU new 2019 masthead1

November 1, 2004

View Archives Issues

  • New contraceptives widen choices, but the Pill still is a top selection

    While the contraceptive transdermal patch (Ortho Evra, Ortho-McNeil Pharmaceutical, Raritan, NJ) and the contraceptive vaginal ring (NuvaRing, Organon, West Orange, NJ) are gaining increased use among women, many providers report that oral contraceptives (OCs) remain a popular form of birth control.
  • Survey Profile

  • Pill remains powerful force in contraception

    Take a look at the last 10 patient charts in your outbox. If oral contraceptives (OCs) were prescribed, which ones were selected? When it comes to prescriptions for younger women, about 24% of respondents to the 2004 Contraceptive Technology Update Contraception Survey say their No. 1 pill of choice is Ortho Tri-Cyclen Lo (Ortho-McNeil Pharmaceutical, Raritan, NJ).
  • Providing pills: Readers speak out

    When it comes to oral contraceptives (OCs), when should pills be prescribed, and when should they be withheld? Respondents to the 2004 Contraceptive Technology Update Contraception Survey take a cautious approach when it comes to providing pills for older women who smoke.
  • More women are looking at intrauterine devices

    Are more women at your family planning facility requesting information on intrauterine contraception? Chances are you are seeing an increase in interest: Almost 30% of respondents to the 2004 Contraceptive Technology Update Contraception Survey say they have performed six to 25 intrauterine device (IUD) insertions in the last year, up slightly from 2003s figures.
  • New study eyes link to DMPA use, STD risk

    Findings from a just-published study indicate that women who use the contraceptive injection depot medroxyprogesterone acetate (DMPA, marketed as Depo-Provera, Pfizer, New York City) appear to have a threefold increased risk of acquiring chlamydia and gonorrhea when compared to women not using a hormonal contraceptive.
  • DMPA: Check snapshot of current clinical use

    The next patient in your exam room is a 16-year-old young woman who says she needs effective contraception. She has tried oral contraceptives (OCs), but she says she has trouble remembering to take a daily pill. What options can you offer her?